The Effect of Dorzolamide-timolol Eye drop on Intraocular Pressure Change in Intravitreal Ranibizumab Injected Patients.

IF 0.5 Q4 OPHTHALMOLOGY

Middle East African Journal of Ophthalmology Pub Date : 2024-06-14 eCollection Date: 2023-04-01 DOI:10.4103/meajo.meajo_177_23

Mehmet Coşkun

{"title":"The Effect of Dorzolamide-timolol Eye drop on Intraocular Pressure Change in Intravitreal Ranibizumab Injected Patients.","authors":"Mehmet Coşkun","doi":"10.4103/meajo.meajo_177_23","DOIUrl":null,"url":null,"abstract":"Purpose: The objective of the study was to examine the effect of dorzolamide-timolol (DT) eye drop used before intravitreal ranibizumab (IVR) injection on intraocular pressure (IOP) change.Methods: 50 eyes of 50 patients who received DT eye drops 1 h before IVR injection due to diabetic retinopathy and macular edema were considered Group 1, and 50 eyes of 50 patients who did not receive DT eye drops were considered Group 2. Those patients who had previously undergone intravitreal injection had intraocular surgery, and used any eye drops were not included in the study. Before the injection, IOP values were measured with a Tonopen contact handheld tonometer before the blepharostat was placed (BIOP), after the blepharostat was placed (AIOP), and at the 1st min after the injection (IIOP).Results: There were 25 males and 25 females in Group 1 and 25 males and 25 females in Group 2; the mean age was 65.66 ± 9.94 years in Group 1 and 65.54 ± 7.43 years in Group 2 (P = 0.98). In Group 1, BIOP was 18.91 ± 18.91, AIOP was 21.62 ± 6.16 mmHg, and IIOP was 49.21 ± 10.95 mmHg. In Group 2, BIOP was 20.18 ± 4.19 mmHg, AIOP was 24.60 ± 4.90 mmHg, and IIOP was 49.96 ± 9.72 mmHg. IIOP-BIOP difference was 30.30 ± 9.85 mmHg in Group 1 and 29.78 ± 9.33 mmHg in Group 2 and the difference was not statistically significant (P = 0.78). In Group 1, the IIOP-AIOP difference was 27.58 ± 10.60 mmHg and in Group 2, 25.36 ± 10.46 mmHg. The difference between IIOP and AIOP was not statistically significant (P = 0.27).Conclusion: The use of topical DT eye drops before IVR injection does not affect the intraocular pressure change.","PeriodicalId":18740,"journal":{"name":"Middle East African Journal of Ophthalmology","volume":"30 2","pages":"85-88"},"PeriodicalIF":0.5000,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11238931/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Middle East African Journal of Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/meajo.meajo_177_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/4/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The objective of the study was to examine the effect of dorzolamide-timolol (DT) eye drop used before intravitreal ranibizumab (IVR) injection on intraocular pressure (IOP) change.

Methods: 50 eyes of 50 patients who received DT eye drops 1 h before IVR injection due to diabetic retinopathy and macular edema were considered Group 1, and 50 eyes of 50 patients who did not receive DT eye drops were considered Group 2. Those patients who had previously undergone intravitreal injection had intraocular surgery, and used any eye drops were not included in the study. Before the injection, IOP values were measured with a Tonopen contact handheld tonometer before the blepharostat was placed (BIOP), after the blepharostat was placed (AIOP), and at the 1^st min after the injection (IIOP).

Results: There were 25 males and 25 females in Group 1 and 25 males and 25 females in Group 2; the mean age was 65.66 ± 9.94 years in Group 1 and 65.54 ± 7.43 years in Group 2 (P = 0.98). In Group 1, BIOP was 18.91 ± 18.91, AIOP was 21.62 ± 6.16 mmHg, and IIOP was 49.21 ± 10.95 mmHg. In Group 2, BIOP was 20.18 ± 4.19 mmHg, AIOP was 24.60 ± 4.90 mmHg, and IIOP was 49.96 ± 9.72 mmHg. IIOP-BIOP difference was 30.30 ± 9.85 mmHg in Group 1 and 29.78 ± 9.33 mmHg in Group 2 and the difference was not statistically significant (P = 0.78). In Group 1, the IIOP-AIOP difference was 27.58 ± 10.60 mmHg and in Group 2, 25.36 ± 10.46 mmHg. The difference between IIOP and AIOP was not statistically significant (P = 0.27).

Conclusion: The use of topical DT eye drops before IVR injection does not affect the intraocular pressure change.

查看原文本刊更多论文

多佐胺-噻吗洛尔滴眼液对注射玻璃体内雷珠单抗患者眼压变化的影响

目的：该研究旨在探讨玻璃体内注射雷尼珠单抗（IVR）前使用多佐胺-噻吗洛尔（DT）滴眼液对眼压（IOP）变化的影响。方法：将因糖尿病视网膜病变和黄斑水肿而在注射 IVR 前 1 小时滴用多佐胺-噻吗洛尔（DT）眼药水的 50 名患者的 50 只眼睛视为第一组，未滴用 DT 眼药水的 50 名患者的 50 只眼睛视为第二组。注射前，使用 Tonopen 接触式手持眼压计测量放置眼睑板前（BIOP）、放置眼睑板后（AIOP）和注射后 1 分钟（IIOP）的眼压值：第一组有 25 名男性和 25 名女性，第二组有 25 名男性和 25 名女性；第一组的平均年龄为（65.66 ± 9.94）岁，第二组的平均年龄为（65.54 ± 7.43）岁（P = 0.98）。第 1 组的 BIOP 为（18.91±18.91）mmHg，AIOP 为（21.62±6.16）mmHg，IIOP 为（49.21±10.95）mmHg。第二组的 BIOP 为 20.18 ± 4.19 mmHg，AIOP 为 24.60 ± 4.90 mmHg，IIOP 为 49.96 ± 9.72 mmHg。第 1 组 IIOP-BIOP 差值为 30.30 ± 9.85 mmHg，第 2 组为 29.78 ± 9.33 mmHg，差异无统计学意义（P = 0.78）。第 1 组的 IIOP-AIOP 差值为 27.58 ± 10.60 mmHg，第 2 组为 25.36 ± 10.46 mmHg。IIOP 和 AIOP 之间的差异无统计学意义（P = 0.27）：结论：IVR 注射前局部滴用 DT 眼药水不会影响眼压变化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Middle East African Journal of Ophthalmology OPHTHALMOLOGY-

CiteScore

1.40

自引率

0.00%

发文量

期刊介绍： The Middle East African Journal of Ophthalmology (MEAJO), published four times per year in print and online, is an official journal of the Middle East African Council of Ophthalmology (MEACO). It is an international, peer-reviewed journal whose mission includes publication of original research of interest to ophthalmologists in the Middle East and Africa, and to provide readers with high quality educational review articles from world-renown experts. MEAJO, previously known as Middle East Journal of Ophthalmology (MEJO) was founded by Dr Akef El Maghraby in 1993.